A groundbreaking Kiwi-developed therapy has been shown to be safer than its leading overseas counterparts at treating certain types of blood cancer, while staying effective.
Promising results revealed today mark the latest milestone in a six-year push toward a new generation of CAR T-cell therapy - in which a patient’s own immune or T-cells are genetically modified to recognise and destroy their cancer.
Dubbed Enable - and arising from a joint venture between Wellington’s Malaghan Institute and China’s Hunan Zhaotai Medical Group - the effort aimed to develop a CAR-T cell treatment as effective and safer than existing ones.
In phase one clinical trials, CAR T-cells created and manufactured in Wellington have been used in 21 patients with specific types of lymphoma, and who’d exhausted their options for treatment.
The results, published online today, showed around half of the participants’ lymphomas to be in complete response three months after receiving the therapy.